表紙
市場調查報告書

肝細胞癌(HCC)- 市場洞察,流行病學,預測 2028年

Hepatocellular Carcinoma Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 534788
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
肝細胞癌(HCC)- 市場洞察,流行病學,預測 2028年 Hepatocellular Carcinoma Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

肝細胞癌(HCC),是最常見的原發性肝細胞癌症。肝細胞癌(HCC)是第5大癌症,其發生率由於B型及C型肝炎病毒感染的擴大在全世界增加。主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的肝細胞癌(HCC)的2017年的罹患數為10萬5,785人,同年的市場規模18億4,170萬美元估計。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的肝細胞癌(HCC)市場相關調查,疾病概要和現行的治療方法,已上市治療藥及新藥的簡介,主要7個國家的市場趨勢,流行病學的預測,市場規模,各市場區隔的罹患數的變化與預測,未滿足需求,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 重要洞察

第2章 肝細胞癌(HCC)市場概要

  • 肝細胞癌(HCC)的分佈(實在數值)
  • 肝細胞癌(HCC)的分佈(預測值)

第3章 疾病背景和概要:肝細胞癌(HCC)

  • 簡介
  • 症狀
  • 肝細胞癌的病期分類
  • 病因和危險因素
  • 病理生理學
  • 診斷
  • 診斷指南

第4章 流行病學和患者人口

  • 主要調查結果
  • 人口與預測參數
  • 主要7個國家的肝細胞癌的總罹患數

第5章 肝細胞癌(HCC)的流行病學:各國

  • 美國
    • 肝細胞癌(HCC)的總罹患數
    • 進展肝細胞癌(HCC)的罹患數
    • 肝細胞癌(HCC)的罹患數:性別
    • 肝細胞癌(HCC)的患病數:各病因
  • 歐盟5國
    • 德國
      • 肝細胞癌(HCC)的總罹患數
      • 進展肝細胞癌(HCC)的罹患數
      • 肝細胞癌(HCC)的罹患數:性別
      • 肝細胞癌(HCC)的患病數:各病因
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本
    • 肝細胞癌(HCC)的總罹患數
    • 肝細胞癌(HCC)的罹患數:2次各類型
    • 肝細胞癌(HCC)的罹患數:性別
    • 肝細胞癌(HCC)的患病數:各病期

第6章 治療的實踐

  • 治療目標
  • NCCN臨床診療指南為基礎治療流程
  • 肝細胞癌的治療的AASLD指南
  • HCC管理指南:歐洲醫療腫瘤學會(ESMO)
  • 早期及中期HCC的管理
  • 進展疾病的管理
  • 跟蹤、長期的影響、存活率

第7章 未滿足需求

第8章 貢獻組織

第9章 已上市治療藥

  • Nexavar:Bayer HealthCare
    • 產品概要
    • 作用機制
    • 法規的里程碑
    • 優點與缺點
    • 安全性和有效性
    • 產品簡介
  • Miripla:大日本住友製藥
  • Opdivo:Bristol-Myers Squibb
  • Pembrolizumab (Keytruda):Merck & Co.
  • Stivarga:Bayer Pharma
  • Ramucirumab (Cyramza):Eli Lilly and Co.
  • Cabometyx:Exelixis Inc.
  • Lenvima:Merck/Eisai

第10章 新藥

  • 新藥分析
    • Tislelizumab (BGB-A317):BeiGene
    • Durvalumab (Imfinzi):Astra Zeneca
    • Milciclib:Tiziana Life Sciences
  • 聯合治療分析
  • 第三階段肝細胞癌臨床實驗的失敗

第11章 其他的有力候補藥

  • Namodenoson (CF 102):Can-Fite BioPharma
  • Capmatinib:Eli Lilly and Co.
  • Palbociclib: Pfizer
  • ENMD2076: CASI Pharmaceuticals
  • HCC011: Tera Bio-Pharma

第12章 個案研究

  • 切除無能的肝細胞癌
  • 青年成人的肝細胞癌

第13章 主要7個國家的肝細胞癌(HCC)市場分析

  • 主要調查結果
  • 主要7個國家的整體市場規模
  • 主要7個國家的市場規模:各治療線

第14章 各國市場預測

  • 美國的市場預測
  • 美國的市場規模
    • 整體市場規模
    • 市場規模:各治療線
    • 市場規模:各一線藥物
    • 市場規模:各二線藥物
  • 德國的市場規模
  • 法國的市場規模
  • 義大利的市場規模
  • 西班牙的市場規模
  • 英國的市場規模
  • 日本的市場規模

第15章 市場成長要素

第16章 市場障礙

第17章 附錄

第18章 調查手法

第19章 DelveInsight的服務內容

第20章 免責聲明

第21章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0348

DelveInsight's "Hepatocellular Carcinoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Hepatocellular Carcinoma, historical and forecasted epidemiology as well as the Hepatocellular Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Hepatocellular Carcinoma market report provides current treatment practices, emerging drugs, Hepatocellular Carcinoma market share of the individual therapies, current and forecasted Hepatocellular Carcinoma market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hepatocellular Carcinoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Hepatocellular Carcinoma Disease Understanding and Treatment Algorithm

The DelveInsight Hepatocellular Carcinoma market report gives a thorough understanding of the Hepatocellular Carcinoma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Hepatocellular Carcinoma.

Treatment

It covers the details of conventional and current medical therapies available in the Hepatocellular Carcinoma market for the treatment of the condition. It also provides Hepatocellular Carcinoma treatment algorithms and guidelines in the United States, Europe, and Japan.

Hepatocellular Carcinoma Epidemiology

The Hepatocellular Carcinoma epidemiology division provide insights about historical and current Hepatocellular Carcinoma patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Hepatocellular Carcinoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Hepatocellular Carcinoma Epidemiology

The epidemiology segment also provides the Hepatocellular Carcinoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Hepatocellular Carcinoma Drug Chapters

Drug chapter segment of the Hepatocellular Carcinoma report encloses the detailed analysis of Hepatocellular Carcinoma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Hepatocellular Carcinoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Hepatocellular Carcinoma treatment.

Hepatocellular Carcinoma Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Hepatocellular Carcinoma treatment.

Hepatocellular Carcinoma Market Outlook

The Hepatocellular Carcinoma market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Hepatocellular Carcinoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Hepatocellular Carcinoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Hepatocellular Carcinoma market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Hepatocellular Carcinoma market in 7MM.

The United States Market Outlook

This section provides the total Hepatocellular Carcinoma market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Hepatocellular Carcinoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Hepatocellular Carcinoma market size and market size by therapies in Japan is also mentioned.

Hepatocellular Carcinoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Hepatocellular Carcinoma market or expected to get launched in the market during the study period 2017-2030. The analysis covers Hepatocellular Carcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Hepatocellular Carcinoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Hepatocellular Carcinoma key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Hepatocellular Carcinoma emerging therapies.

Reimbursement Scenario in Hepatocellular Carcinoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Hepatocellular Carcinoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Hepatocellular Carcinoma market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Hepatocellular Carcinoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Hepatocellular Carcinoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Hepatocellular Carcinoma epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hepatocellular Carcinoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Hepatocellular Carcinoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hepatocellular Carcinoma market

Report Highlights

  • In the coming years, Hepatocellular Carcinoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Hepatocellular Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Hepatocellular Carcinoma. Launch of emerging therapies will significantly impact the Hepatocellular Carcinoma market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hepatocellular Carcinoma
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Hepatocellular Carcinoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Hepatocellular Carcinoma Pipeline Analysis
  • Hepatocellular Carcinoma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Hepatocellular Carcinoma Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Hepatocellular Carcinoma Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Hepatocellular Carcinoma Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Hepatocellular Carcinoma market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Hepatocellular Carcinoma total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Hepatocellular Carcinoma market size during the forecast period (2017-2030)?
  • At what CAGR, the Hepatocellular Carcinoma market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Hepatocellular Carcinoma market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Hepatocellular Carcinoma market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Hepatocellular Carcinoma?
  • What is the historical Hepatocellular Carcinoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Hepatocellular Carcinoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hepatocellular Carcinoma?
  • Out of all 7MM countries, which country would have the highest prevalent population of Hepatocellular Carcinoma during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Hepatocellular Carcinoma treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Hepatocellular Carcinoma in the USA, Europe, and Japan?
  • What are the Hepatocellular Carcinoma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Hepatocellular Carcinoma?
  • How many therapies are developed by each company for Hepatocellular Carcinoma treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Hepatocellular Carcinoma treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Hepatocellular Carcinoma therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hepatocellular Carcinoma and their status?
  • What are the key designations that have been granted for the emerging therapies for Hepatocellular Carcinoma?
  • What are the global historical and forecasted market of Hepatocellular Carcinoma?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Hepatocellular Carcinoma market
  • To understand the future market competition in the Hepatocellular Carcinoma market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Hepatocellular Carcinoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Hepatocellular Carcinoma market
  • To understand the future market competition in the Hepatocellular Carcinoma market

Table of Contents

1. Key Insights

2. Executive Summary of Hepatocellular Carcinoma

3. Competitive Intelligence Analysis for Hepatocellular Carcinoma

4. Hepatocellular Carcinoma: Market Overview at a Glance

  • 4.1. Hepatocellular Carcinoma Total Market Share (%) Distribution in 2017
  • 4.2. Hepatocellular Carcinoma Total Market Share (%) Distribution in 2030

5. Hepatocellular Carcinoma: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Hepatocellular Carcinoma Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Hepatocellular Carcinoma Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Hepatocellular Carcinoma Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Hepatocellular Carcinoma Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Hepatocellular Carcinoma Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Hepatocellular Carcinoma Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Hepatocellular Carcinoma Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Hepatocellular Carcinoma Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Hepatocellular Carcinoma Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Hepatocellular Carcinoma Treatment and Management
  • 8.2. Hepatocellular Carcinoma Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Hepatocellular Carcinoma Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Hepatocellular Carcinoma: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Hepatocellular Carcinoma Market Size in 7MM
  • 13.3. Hepatocellular Carcinoma Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Hepatocellular Carcinoma Total Market Size in the United States
    • 15.1.2. Hepatocellular Carcinoma Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Hepatocellular Carcinoma Total Market Size in Germany
    • 15.3.2. Hepatocellular Carcinoma Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Hepatocellular Carcinoma Total Market Size in France
    • 15.4.2. Hepatocellular Carcinoma Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Hepatocellular Carcinoma Total Market Size in Italy
    • 15.5.2. Hepatocellular Carcinoma Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Hepatocellular Carcinoma Total Market Size in Spain
    • 15.6.2. Hepatocellular Carcinoma Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Hepatocellular Carcinoma Total Market Size in the United Kingdom
    • 15.7.2. Hepatocellular Carcinoma Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Hepatocellular Carcinoma Total Market Size in Japan
    • 15.8.3. Hepatocellular Carcinoma Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Hepatocellular Carcinoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Hepatocellular Carcinoma Epidemiology (2017-2030)
  • Table 2 : 7MM Hepatocellular Carcinoma Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Hepatocellular Carcinoma Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Hepatocellular Carcinoma Epidemiology in Germany (2017-2030)
  • Table 6 : Hepatocellular Carcinoma Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Hepatocellular Carcinoma Epidemiology in France (2017-2030)
  • Table 8 : Hepatocellular Carcinoma Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Hepatocellular Carcinoma Epidemiology in Italy (2017-2030)
  • Table 10 : Hepatocellular Carcinoma Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Hepatocellular Carcinoma Epidemiology in Spain (2017-2030)
  • Table 12 : Hepatocellular Carcinoma Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Hepatocellular Carcinoma Epidemiology in the UK (2017-2030)
  • Table 14 : Hepatocellular Carcinoma Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Hepatocellular Carcinoma Epidemiology in Japan (2017-2030)
  • Table 16 : Hepatocellular Carcinoma Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Hepatocellular Carcinoma Epidemiology (2017-2030)
  • Figure 2 : 7MM Hepatocellular Carcinoma Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Hepatocellular Carcinoma Epidemiology in the United States (2017-2030)
  • Figure 4 : Hepatocellular Carcinoma Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Hepatocellular Carcinoma Epidemiology in Germany (2017-2030)
  • Figure 6 : Hepatocellular Carcinoma Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Hepatocellular Carcinoma Epidemiology in France (2017-2030)
  • Figure 8 : Hepatocellular Carcinoma Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Hepatocellular Carcinoma Epidemiology in Italy (2017-2030)
  • Figure 10 : Hepatocellular Carcinoma Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Hepatocellular Carcinoma Epidemiology in Spain (2017-2030)
  • Figure 12 : Hepatocellular Carcinoma Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Hepatocellular Carcinoma Epidemiology in the UK (2017-2030)
  • Figure 14 : Hepatocellular Carcinoma Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Hepatocellular Carcinoma Epidemiology in Japan (2017-2030)
  • Figure 16 : Hepatocellular Carcinoma Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)